<?xml version='1.0' encoding='utf-8'?>
<document id="28821485"><sentence text="Simple Evaluation Method for CYP3A4 Induction from Human Hepatocytes: The Relative Factor Approach with an Induction Detection Limit Concentration Based on the Emax Model." /><sentence text="We investigated the robustness and utility of the relative factor (RF) approach based on the maximum induction effect (Emax) model, using the mRNA induction data of 10 typical CYP3A4 inducers in cryopreserved human hepatocytes" /><sentence text=" The RF value is designated as the ratio of the induction detection limit concentration (IDLC) for a standard inducer, such as rifampicin (RIF) or phenobarbital (PB), to that for the compound (e"><entity charOffset="127-137" id="DDI-PubMed.28821485.s3.e0" text="rifampicin" /><entity charOffset="139-142" id="DDI-PubMed.28821485.s3.e1" text="RIF" /><entity charOffset="147-160" id="DDI-PubMed.28821485.s3.e2" text="phenobarbital" /><entity charOffset="162-164" id="DDI-PubMed.28821485.s3.e3" text="PB" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e0" e2="DDI-PubMed.28821485.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e0" e2="DDI-PubMed.28821485.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e0" e2="DDI-PubMed.28821485.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e0" e2="DDI-PubMed.28821485.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e1" e2="DDI-PubMed.28821485.s3.e1" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e1" e2="DDI-PubMed.28821485.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e1" e2="DDI-PubMed.28821485.s3.e3" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e2" e2="DDI-PubMed.28821485.s3.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s3.e2" e2="DDI-PubMed.28821485.s3.e3" /></sentence><sentence text="g" /><sentence text=", RFRIF is IDLCRIF/IDLCcpd; RFPB is IDLCPB/IDLCcpd)"><entity charOffset="4-5" id="DDI-PubMed.28821485.s5.e0" text="RIF" /><entity charOffset="15-16" id="DDI-PubMed.28821485.s5.e1" text="RIF" /><entity charOffset="30-31" id="DDI-PubMed.28821485.s5.e2" text="PB" /><entity charOffset="40-41" id="DDI-PubMed.28821485.s5.e3" text="PB" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e0" e2="DDI-PubMed.28821485.s5.e0" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e0" e2="DDI-PubMed.28821485.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e0" e2="DDI-PubMed.28821485.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e0" e2="DDI-PubMed.28821485.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e1" e2="DDI-PubMed.28821485.s5.e1" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e1" e2="DDI-PubMed.28821485.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e1" e2="DDI-PubMed.28821485.s5.e3" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e2" e2="DDI-PubMed.28821485.s5.e2" /><pair ddi="false" e1="DDI-PubMed.28821485.s5.e2" e2="DDI-PubMed.28821485.s5.e3" /></sentence><sentence text=" An important feature of the RF approach is that the profiles of the induction response curves on the logarithmic scale remain unchanged irrespective of inducers but are shifted parallel depending on the EC50 values" /><sentence text=" A key step in the RF approach is to convert the induction response curve by finding the IDLC of a standard inducer" /><sentence text=" The relative induction score was estimated not only from Emax and EC50 values but also from those calculated by the RF approach" /><sentence text=" These values showed good correlation, with a correlation coefficient of more than 0" /><sentence text="974, which revealed the RF approach to be a robust analysis irrespective of its simplicity" /><sentence text=" Furthermore, the relationship between RFRIF or RFPB multiplied by the steady-state unbound plasma concentration and the in vivo induction ratio plotted using 10 typical inducers gives adequate thresholds for CYP3A4 drug-drug interaction risk assessment"><entity charOffset="41-42" id="DDI-PubMed.28821485.s11.e0" text="RIF" /><entity charOffset="50-51" id="DDI-PubMed.28821485.s11.e1" text="PB" /><pair ddi="false" e1="DDI-PubMed.28821485.s11.e0" e2="DDI-PubMed.28821485.s11.e0" /><pair ddi="false" e1="DDI-PubMed.28821485.s11.e0" e2="DDI-PubMed.28821485.s11.e1" /></sentence><sentence text=" In light of these findings, the simple RF approach using the IDLC value could be a useful method to adequately assess the risk of CYP3A4 induction in humans during drug discovery and development without evaluation of Emax and EC50" /><sentence text="" /></document>